The investment seeks investment results that, before expenses, correspond generally to the price and yield performance of publicly traded equity securities of companies in the Health Care Select Sector Index... Show more
The Health Care Select Sector SPDR Fund tracks the Health Care Select Sector Index, a market-capitalization-weighted basket of health care companies drawn from the S&P 500. It employs a replication strategy, investing at least 95% of its assets in the underlying index constituents, and carries a low expense ratio of 0.08%. The portfolio is concentrated in large-cap U.S. names, with roughly 97.6% of exposure in the United States.
Industry exposure tilts heavily toward pharmaceuticals (about 37%), health care equipment and supplies, health care providers and services, and life sciences tools and services. The top holdings include LLY (Eli Lilly, roughly 15%), JNJ (Johnson & Johnson), ABBV (AbbVie), UNH (UnitedHealth Group), and MRK (Merck). This concentration means the fund's future performance is closely tied to a handful of mega-cap drugmakers and managed-care leaders.
Structurally, the fund behaves as a defensive growth vehicle. Its beta to the broader market is historically modest, and demand for its underlying services and treatments is relatively insulated from economic cycles. That positioning shapes how it may respond to shifting market trends: it can act as a portfolio stabilizer when growth-oriented sectors wobble, while still offering exposure to secular innovation in drug development and medical technology.
Several developments could materially influence the fund's trajectory in the coming quarters.
The broader macro environment is central to the fund's macro outlook. After trading at a steep discount to the S&P 500 for much of the past few years, the health care sector has re-rated sharply, with its forward price-to-earnings multiple now roughly in line with, or slightly above, the broad index. That shifts the emphasis from valuation recovery to earnings delivery.
Earnings visibility is improving: S&P 500 health care companies are forecast to post double-digit profit growth beginning in late 2026, a sharp contrast to prior years. Meanwhile, concerns over tariffs and U.S. drug-pricing policy have eased, allowing investors to refocus on fundamentals. Hedge fund positioning in the sector has also climbed toward multi-year highs.
The rotation out of crowded artificial-intelligence and technology trades has been a powerful near-term tailwind, directing fresh capital toward defensive growth. However, this cuts both ways: if AI-related anxiety subsides, capital could rotate back, pressuring the sector's newly re-rated multiple even if underlying businesses remain sound. Interest rates, inflation trends, and equity market leadership will therefore continue to shape the sector outlook.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool designed to help traders assess whether a stock, ETF, or other asset may trend bullish, bearish, or sideways over the coming week or month. It supports users in spotting developing trends, evaluating potential breakouts or reversals, and exploring predictions across a wide range of tradable instruments. The platform organizes predictions into searchable categories, provides historical context, and includes alert-oriented functionality to help users monitor changing signals. For investors tracking the future outlook of health care assets, tools like this can complement fundamental analysis by offering a systematic, data-driven view of near-term directional bias. Consider exploring the Trend Prediction Engine to see how its AI-based signals apply to the assets on your watchlist.
Beyond near-term rotation dynamics, several structural forces support the fund's long-term investment case. Aging demographics are a foundational driver: an expanding population of older adults in developed markets is expected to sustain demand for pharmaceuticals, medical devices, and health care services well into the next decade. Health care spending tends to remain resilient even during economic downturns, giving the sector defensive qualities that can buffer portfolios during periods of market turbulence.
Innovation is a second pillar. GLP-1 therapies are projected to become a $100 billion-plus global market by 2030, while personalized mRNA cancer vaccines and advances in immunology are broadening the pipeline. Artificial intelligence is also shifting from a pure technology theme into an operational tailwind, helping biopharma firms accelerate drug discovery and clinical trials and enabling health systems to reduce administrative costs.
At the same time, structural risks remain. Patent expirations at major drugmakers, pricing reform, and the sector's now-higher valuation multiple could temper long-run returns if earnings growth disappoints. The index's heavy concentration in a handful of mega-cap names also means single-stock outcomes can meaningfully sway the fund's trajectory. Investors weighing this exposure should consider how these long-term drivers and risks align with their own portfolio objectives.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SDOW | 30.46 | 1.64 | +5.69% |
| ProShares UltraPro Short Dow30 (SDOW) | |||
| PMOC | 26.12 | -0.17 | -0.63% |
| PGIM S&P 500 Max Buffer ETF - October (PMOC) | |||
| DECU | 27.38 | -0.43 | -1.55% |
| AllianzIM U.S. Equity Buffer15 Uncapped Dec ETF (DECU) | |||
| BINV | 43.19 | -0.68 | -1.56% |
| Brandes International ETF (BINV) | |||
| JGLO | 65.26 | -2.48 | -3.66% |
| JPMorgan Global Select Equity ETF Global Select Equity ETF (JGLO) | |||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| JGLO | 65.26 | -2.48 | -3.66% |
| JPMorgan Global Select Equity ETF Global Select Equity ETF (JGLO) | |||
| BINV | 43.19 | -0.68 | -1.56% |
| Brandes International ETF (BINV) | |||
| DECU | 27.38 | -0.43 | -1.55% |
| AllianzIM U.S. Equity Buffer15 Uncapped Dec ETF (DECU) | |||
| PMOC | 26.12 | -0.17 | -0.63% |
| PGIM S&P 500 Max Buffer ETF - October (PMOC) | |||
| SDOW | 30.46 | 1.64 | +5.69% |
| ProShares UltraPro Short Dow30 (SDOW) | |||
A.I.dvisor indicates that over the last year, XLV has been closely correlated with IYH. These tickers have moved in lockstep 99% of the time. This A.I.-generated data suggests there is a high statistical probability that if XLV jumps, then IYH could also see price increases.
| Ticker / NAME | Correlation To XLV | 1D Price Change % | ||
|---|---|---|---|---|
| XLV | 100% | -0.12% | ||
| IYH - XLV | 99% Closely correlated | -0.32% | ||
| FHLC - XLV | 99% Closely correlated | -0.39% | ||
| VHT - XLV | 99% Closely correlated | -0.40% | ||
| IXJ - XLV | 97% Closely correlated | -0.50% | ||
| RSPH - XLV | 88% Closely correlated | -0.95% | ||
More | ||||
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where XLV declined for three days, in 250 of 308 cases, the price declined further within the following month. The odds of a continued downward trend are 81%.
The 10-day RSI Indicator for XLV moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 27 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 73%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XLV as a result. In 72 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
The Moving Average Convergence Divergence Histogram (MACD) for XLV turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 38 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The 10-day moving average for XLV crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 77%.
Following a +0.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where XLV advanced for three days, in 264 of 325 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
XLV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 225 of 273 cases where XLV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.